Companies · Biotechnology

KIYATEC Inc.

GREENVILLE · Biotechnology

Diligence memoA one-page analyst read on KIYATEC Inc. — recommendation, valuation, rhythm, risks.
$32.3M
Total raised · real
8
Rounds
1.0×
Latest step-up
Top 25%
Sector rank · raised
Series B
Latest stage · inferred · Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

KIYATEC Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.01× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
  • Issuer reports $1M–$5M revenue while modeled below niche peers.
Quiet
  • Last raise 20 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

KIYATEC Inc. is one of 4293 Biotechnology companies tracked from GREENVILLE. By capital raised it ranks in the upper tier (ahead of 76% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(b)
Reg D exemption
1
Investors (latest)
2024-10-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2012-07-01 Raised $2.8M (real) Modeled valuation $125M (est)Seed2012Seed · 2014-07-01 Raised $501K (real) Modeled valuation $22M (est)Seed2014Seed · 2014-11-06 Raised $180K (real) Modeled valuation $8.0M (est)Seed2014Seed · 2015-07-01 Raised $3.1M (real) Modeled valuation $140M (est)Seed2015Seed · 2015-11-09 Raised $3.1M (real) Modeled valuation $140M (est)Seed2015Seed · 2017-07-01 Raised $2.0M (real) Modeled valuation $89M (est)Seed2017Series A · 2019-02-22 Raised $5.3M (real) Modeled valuation $193M (est)Series A2019Series B · 2022-11-23 Raised $18M (real) Modeled valuation $256M (est)Series B2022Pre-Seed · 2024-10-22 Raised $250K (real) Modeled valuation $953K (est)Pre-Seed2024Series B · 2024-10-22 Raised $250K (real) Modeled valuation $1.6M (est)Series B2024+$501K+$180K+$3.1M+$3.1M+$2.0M+$5.3M+$18M+$250K+$250KCumulative $36M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$2.8M · 2012
Seed extension$501K · 2014
Seed extension$180K · 2014
Seed extension$3.1M · 2015
Seed extension$3.1M · 2015
Seed extension$2.0M · 2017
Series A$5.3M · 2019
Series B$18.1M · 2022
Bridge · Series B-stage$250K · 2024smaller follow-on
Series B extension$250K · 2024

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$1.6M
Base estimate est.
$500K
Conservative case
$2.6M
Upside case
$1.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $125.3M · 2012-07-012012Seed · modeled $22.2M · 2014-07-01Seed · modeled $8.0M · 2014-11-06Seed · modeled $139.8M · 2015-07-01Seed · modeled $139.8M · 2015-11-09Seed · modeled $88.8M · 2017-07-01Series A · modeled $192.7M · 2019-02-22Series B · modeled $256.5M · 2022-11-23Pre-Seed · modeled $953K · 2024-10-22Series B · modeled $1.6M · 2024-10-222024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
1.7 yr
Elapsed time used
1.7 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
16 mo
Avg between rounds
$2.6M/yr
Capital velocity
14.0 yr
On record since
2012
First round
10
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.5× above median
This company$32.3M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.0× of median
This company$250K
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$1.6M
Sector median$64.2M

Raised more than 76% of sector peers (real $). Modeled value above 4% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #197 of 197.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Mt McKinley Medical Holding Corp USA · Series B Raised $40.0M · modeled $738.4M (est)YAP Therapeutics Inc · Series B Raised $30.1M · modeled $618.3M (est)Pinteon Therapeutics, Inc. · Series B Raised $39.2M · modeled $603.8M (est)OncXerna Therapeutics, Ltd. · Series B Raised $30.0M · modeled $591.4M (est)EpiBiologics, Inc. · Series B Raised $30.0M · modeled $570.2M (est)GIOGI Ltd · Series B Raised $27.3M · modeled $554.5M (est)SonoThera, Inc. · Series B Raised $30.4M · modeled $550.9M (est)Perceive Biotherapeutics, Inc. · Series B Raised $40.0M · modeled $544.6M (est)GIOCAN Ltd · Series B Raised $24.5M · modeled $498.6M (est)GIODIA Ltd · Series B Raised $24.5M · modeled $498.6M (est)GIOHEALTH Ltd · Series B Raised $24.5M · modeled $498.6M (est)Cerapedics Inc · Series B Raised $99.1M · modeled $492.3M (est)KIYATEC Inc. (this company) Raised $32.3M · modeled $1.6M (est)KIYATEC Inc.
CompanyStageRaised · realValue · estvs peer med.
Mt McKinley Medical Holding Corp USASeries B$40.0M$738.4M4.41×
YAP Therapeutics IncSeries B$30.1M$618.3M3.69×
Pinteon Therapeutics, Inc.Series B$39.2M$603.8M3.60×
OncXerna Therapeutics, Ltd.Series B$30.0M$591.4M3.53×
EpiBiologics, Inc.Series B$30.0M$570.2M3.40×
GIOGI LtdSeries B$27.3M$554.5M3.31×
SonoThera, Inc.Series B$30.4M$550.9M3.29×
Perceive Biotherapeutics, Inc.Series B$40.0M$544.6M3.25×
GIOCAN LtdSeries B$24.5M$498.6M2.97×
GIODIA LtdSeries B$24.5M$498.6M2.97×
GIOHEALTH LtdSeries B$24.5M$498.6M2.97×
Cerapedics IncSeries B$99.1M$492.3M2.94×
KIYATEC Inc. this companySeries B$32.3M$1.6M0.01×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$2.8M2012-07-01$14.1M$125.3M85%
Seed$501K2014-07-01$2.5M$22.2M85%
Seed$180K2014-11-06$900K$8.0M85%
Seed$3.1M2015-07-01$15.7M$139.8M85%
Seed$3.1M2015-11-09$15.7M$139.8M90%
Seed$2.0M2017-07-01$10.0M$88.8M90%
Series A$5.3M2019-02-22$24.2M$192.7M90%
Series B$18.1M2022-11-23$100.3M$256.5M90%
Pre-Seed$250K2024-10-22$1.4M$953K90%
Series B$250K2024-10-22$1.4M$1.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$2.8M2012-07-01
    • First recorded raise — entered as Seed.
  2. Seed$501K2014-07-01
    • Raised again after 24 mo — slower than the ~14 mo sector norm.
    • Round 5.6× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 06).
  3. Seed$180K2014-11-06
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 2.8× smaller than the prior — bridge or down round.
    • 3 investors on this round.
  4. Seed$3.1M2015-07-01
    • Came back fast: 8 mo vs the ~14 mo sector norm.
    • Round 17.5× larger than the prior — scaling up.
  5. Seed$3.1M2015-11-09
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 24 investors on this round.
  6. Seed$2.0M2017-07-01
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 1.6× smaller than the prior — bridge or down round.
  7. Series A$5.3M2019-02-22
    • Raised 20 mo later, in step with the ~14 mo sector norm.
    • Round 2.7× larger than the prior — scaling up.
    • 15 investors on this round.
  8. Series B$18.1M2022-11-23
    • Raised again after 45 mo — slower than the ~14 mo sector norm.
    • Round 3.4× larger than the prior — scaling up.
    • 23 investors on this round.
  9. Pre-Seed$250K2024-10-22
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 72.2× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  10. Series B$250K2024-10-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2026 ~Q1
Modeled next raise · ~16mo cadence
$250K
Modeled next size est.range $250K$400K
1.0×
Last step-up
$2.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Robert Silverman4 other2024-10
Jason Robart2 other2024-10
Gregory Zaic1 other2015-07
Robert J. Silverman1 other2017-07
Bob Lee Silverman2014-07
Bob Silverman2015-07
Bruce Nash2024-10
Bruce R. Nash2022-11
Christine Dixon Thiesing2017-07
Christine R. Dixon Thiesing2019-02
Christopher Brotherton2015-07
Christopher E. Brotherton2012-07
Christopher J. Brotherton2017-07
Christopher R. Brotherton2019-02
David E. Orr2012-07
Eric Perreault2024-10
Gregory E Zaic2014-07
Gregory J. Zaic2017-07
Gregory R. Zaic2019-02
H. Lee Higdon III2014-07
Jason R. Robart2022-11
Martin Ettlemyer2015-11
Matthew Gevaert2014-07
Matthew R. Gevaert2012-07
Registry & provenance

KIYATEC Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1547577
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Allarity Therapeutics, Inc.BiotechnologySeries B$26.9M$3.5Msame sector · same stage
Intrommune Therapeutics, Inc.BiotechnologySeries B$25.5M$1.9Msame sector · same stage
MBio Diagnostics, Inc.Medical DevicesSeries A$45.3M$77.4Mnetwork2 shared operators
Mateon Therapeutics IncBiotechnologySeries B$45.3M$1.1Msame sector · same stage
Cirius Therapeutics, Inc.BiotechnologySeries B$49.6M$3.3Msame sector · same stage
Moving Analytics, Inc.Software / TechSeries B$26.4M$319.5Mnetwork1 shared operator · same stage
Smart Health Diagnostics CoBiotechnologySeries B$17.3M$1.8Msame sector · same stage
Alphina Therapeutics, Inc.BiotechnologySeries B$17.0M$541Ksame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Kiffik Biomedical, Inc.BiotechnologyPre-Seed$21.4M87%
Kilele Health Inc.BiotechnologyPre-Seed$569K87%
Kezar Life Sciences, Inc.BiotechnologySeries C$2.0B86%
Kronos Bio, Inc.BiotechnologySeries D+$4.3B86%
Akonni Biosystems IncBiotechnologySeries A$64.2M84%
Kellbenx Inc.BiotechnologySeries A$21.4M84%
Keliomics, Inc.BiotechnologySeed$29.3M84%
miRecule, Inc.BiotechnologySeed$66.6M84%
Frequently asked
How much funding has KIYATEC Inc. raised?
KIYATEC Inc. has raised approximately $32.3M in disclosed capital across 8 recorded financing rounds, aggregated from public filings.
What is KIYATEC Inc.'s estimated valuation?
Provath's modeled valuation for KIYATEC Inc. is approximately $1.6M (modeled range $500K–$2.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is KIYATEC Inc. at?
KIYATEC Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Oct 22.
What does KIYATEC Inc. do and where is it based?
KIYATEC Inc. operates in the Biotechnology sector, based in GREENVILLE.
Explore related

See where KIYATEC Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at KIYATEC Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.